Age [years]
|
61.1 (51.2-68.6)
|
47 (36–59.5)
|
<0.001
| |
Gender, female
|
9 (34.6)
|
168 (44.3)
|
0.33
|
0.66 (0.29-1.53)
|
Referring physician
| | | | |
Inpatients
|
21 (80.8)
|
201 (53.0)
|
<0.01
|
3.80 (1.40-10.28)
|
Outpatients referred by cardiologists
|
5 (19.2)
|
149 (39.3)
|
<0.05
|
0.37 (0.14-0.99)
|
Outpatients referred by general practitioners
|
0
|
29 (7.7)
|
0.14
| |
Primary cardiac symptoms leading to CMR
| | | | |
Reduced LVEF
|
15 (57.7)
|
67 (17.7)
|
<0.0001
|
6.35 (2.79-14.44)
|
Pericardial effusion
|
0
|
6 (1.6)
|
0.52
| |
ECG abnormality
|
7 (26.9)
|
124 (32.7)
|
0.54
|
0.76 (0.31-1.85)
|
Palpitations
|
5 (19.2)
|
87 (23)
|
0.66
|
0.80 (0.29-2.18)
|
Dyspnea
|
18 (69.2)
|
119 (31.4)
|
<0.0001
|
4.92 (2.08-11.62)
|
Angina/Chest pain
|
10 (38.5)
|
207 (54.6)
|
0.11
|
0.52 (0.23-1.17)
|
Abnormal fatigue
|
4 (15.4)
|
92 (24.3)
|
0.30
|
0.57 (0.19-1.68)
|
Wall motion abnormality
|
0
|
17 (4.5)
|
0.27
| |
Ventricular arrythmias/Extrasystoles
|
2 (7.7)
|
43 (11.3)
|
0.57
|
0.65 (0.15-2.85)
|
Aborted SCD
|
0
|
6 (1.6)
|
0.52
| |
Viral Prodrome/history of infectious symptoms
|
4 (15.4)
|
126 (33.2)
|
0.06
|
0.37 (0.05-2.81)
|
Atrial fibrillation
|
9 (34.6)
|
41 (10.8)
|
<0.001
|
4.35 (1.82-10.39)
|
Elevated troponin
|
1 (3.8)
|
37 (9.8)
|
0.32
|
0.37 (0.05-2.81)
|
EMB performed
|
16 (64)
|
62 (17.5)
|
<0.0001
|
8.40 (3.55-19.88)
|
Histological myocarditis in EMB
|
10 (62.5)
|
43 (70.5)
|
0.54
|
0.70 (0.22-2.21)
|
CMR imaging parameters
| | | | |
LVEF [%]
|
39 (22.0-59.0)
|
63 (57.0-69.0)
|
<0.0001
| |
LV-EDV [ml]
|
181 (126.0-284.0)
|
136 (108.0-162.0)
|
<0.001
| |
LV-ESV [ml]
|
123 (52.0-188.0)
|
49 (36.0-67.0)
|
<0.0001
| |
LVEDD [mm]
|
58.5 (54.0-65.0)
|
50 (45.0-54.0)
|
<0.0001
| |
Pericardial effusion present
|
11 (42.3)
|
65 (17.2)
|
<0.01
|
3.53 (1.55-8.04)
|
LGE present
|
18 (69.2)
|
96 (25.5)
|
<0.0001
|
6.59 (2.77-15.63)
|
Final diagnosis based on CMR
| | | | |
No cardiac pathology
|
1 (3.8)
|
224 (59.1)
|
<0.0001
|
6.59 (2.77-15.63)
|
Myocarditis
|
17 (65.4)
|
99 (26.1)
|
<0.0001
|
5.34 (2.31-12.37)
|
Other cardiac pathology
|
8 (30.8)
|
55 (14.5)
|
<0.05
|
2.62 (1.09-6.32)
|
Medication
| | | | |
Betablockers at follow-up
|
20 (87.0)
|
111 (31.8)
|
<0.0001
|
14.29 (4.16-49.11)
|
ACEI/ARB at follow-up
|
20 (87.0)
|
87 (24.09)
|
<0.0001
|
20.08 (5.82-69.20)
|